Sodium Zirconium Cyclosilicate in the Therapeutic Management of Hyperkalemia: A Systematic Review of Efficacy and Safety
Authors:
- Esteban Zavaleta-MonestelEZEsteban Zavaleta-Monestel
- José Andrés Castro-GamboaJCJosé Andrés Castro-Gamboa
- Luis Guillermo Herrera-JiménezLHLuis Guillermo Herrera-Jiménez
- Sebastián Arguedas-ChacónSebastián Arguedas-Chacón
- Jeaustin Mora-JiménezJMJeaustin Mora-Jiménez
- Kevin Cruz-MoraKCKevin Cruz-Mora
- Sofía Granados-RomeroSGSofía Granados-Romero
- José Miguel Chaverri-FernandezJosé Miguel Chaverri-Fernandez
Open Access
- 13 March 2026
- journal article
- review article
- Published by MDPI AG in Kidney and Dialysis
- Vol. 6 (1) , 19
Abstract
Objective: The objective of this study is to evaluate the efficacy and safety of sodium zirconium cyclosilicate in the treatment of hyperkalemia in adult patients based on the available scientific evidence. Methods: A systematic review of randomized controlled trials evaluating SZC in adult patients with hyperkalemia was conducted, including populations with chronic kidney disease and heart failure and patients undergoing hemodialysis. Outcomes assessed included serum potassium reduction, achievement and maintenance of normokalaemia, and adverse events. Results: Seven randomized controlled trials were included. SZC produced a rapid and significant reduction in serum potassium, with reductions of up to 1.28 mmol/L within 48 h and onset of action observed as early as 1–4 h. Across studies, 63–92% of patients achieved normokalaemia within 24–48 h, and maintenance therapy sustained normokalaemia for up to 28 days and longer in selected populations. The most frequently reported adverse events were mild-to-moderate edema and constipation, while hypokalemia was infrequent (<5% in most studies). Conclusions: Sodium zirconium cyclosilicate is an effective and generally well-tolerated option for the management of hyperkalemia, providing rapid potassium reduction and sustained normokalaemia. However, no randomized controlled trial included in this review demonstrated a significant benefit of SZC over comparators in major clinical outcomes—hospitalizations, cardiovascular events, or mortality; the evidence of clinical benefit is therefore absent from the current randomized trial literature.Keywords
This publication has 26 references indexed in Scilit:
- HARMONIZE Asia: A Phase III Randomized Study to Investigate the Efficacy and Safety of Sodium Zirconium Cyclosilicate in Patients with Hyperkalemia in ChinaClinical Therapeutics, 2024
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney DiseaseKidney International, 2024
- DIALIZE China: A Phase IIIb, Randomized, Placebo-Controlled Study to Reduce Predialysis Hyperkalemia With Sodium Zirconium Cyclosilicate in Chinese PatientsClinical Therapeutics, 2023
- Efficacy and safety of potassium binders in the treatment of patients with chronic kidney disease and hyperkalemiaEuropean Journal of Pharmacology, 2022
- Effects and Safety of a Novel Oral Potassium-Lowering Drug-Sodium Zirconium Cyclosilicate for the Treatment of Hyperkalemia: a Systematic Review and Meta-AnalysisCardiovascular Drugs and Therapy, 2021
- Patiromer and Sodium Zirconium Cyclosilicate in Treatment of Hyperkalemia: A Systematic Review and Meta-AnalysisCurrent Therapeutic Research, 2021
- Correction of serum potassium with sodium zirconium cyclosilicate in Japanese patients with hyperkalemia: a randomized, dose–response, phase 2/3 studyClinical and Experimental Nephrology, 2020
- Abnormalities of Potassium in Heart FailureJACC, 2020
- Efficacy and Safety of Sodium Zirconium Cyclosilicate for Hyperkalaemia: The Randomized, Placebo-Controlled HARMONIZE-Global StudyESC Heart Failure, 2020
- Potassium binders for chronic hyperkalaemia in people with chronic kidney diseaseCochrane Database of Systematic Reviews, 2018